What is Erste Group Bank’s Estimate for BMY FY2026 Earnings?

Bristol Myers Squibb Company (NYSE:BMY) – Research analysts at Erste Group Bank dropped their FY2026 earnings per share estimates for shares of Bristol Myers Squibb in a research note issued to investors on Thursday, June 25th. Erste Group Bank analyst H. Engel now forecasts that the biopharmaceutical company will post earnings of $6.31 per share for the year, down from their prior estimate of $6.32. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.32 per share.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. During the same period in the prior year, the business posted $1.80 EPS. Bristol Myers Squibb’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS.

Other research analysts have also recently issued research reports about the stock. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday. Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Cantor Fitzgerald raised their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, April 8th. Finally, Bank of America decreased their price objective on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, April 9th. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $61.31.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock opened at $57.63 on Wednesday. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. Bristol Myers Squibb has a one year low of $42.52 and a one year high of $62.89. The business’s 50 day simple moving average is $57.00 and its two-hundred day simple moving average is $57.41. The stock has a market capitalization of $117.68 billion, a P/E ratio of 16.19, a price-to-earnings-growth ratio of 0.17 and a beta of 0.24.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.

Institutional Trading of Bristol Myers Squibb

Several large investors have recently added to or reduced their stakes in BMY. Swiss RE Ltd. bought a new position in Bristol Myers Squibb in the 4th quarter worth $25,000. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth about $25,000. Physician Wealth Advisors Inc. boosted its stake in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 202 shares in the last quarter. Bayban bought a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at about $31,000. Finally, EQ Wealth Advisors LLC purchased a new position in shares of Bristol Myers Squibb during the fourth quarter valued at about $32,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Unusual options activity turned constructive, with investors buying 53,552 call options on Bristol Myers Squibb, roughly 135% above the stock’s normal call volume. That suggests traders are positioning for more upside.
• Positive Sentiment: Several recent writeups highlighted Bristol Myers Squibb as a top value and momentum name, reinforcing the view that the stock may remain attractive to investors looking for defensive healthcare exposure and earnings stability. Article on BMY as a top value stock
• Neutral Sentiment: Market commentary also pointed to BMY as a stock that recently outperformed the broader market, which may be supporting near-term trading interest but is not a major new fundamental catalyst. Article on BMY exceeding market returns
• Negative Sentiment: One healthcare article raised concern about potential risk from proposed Medicare drug price negotiation updates, which could pressure long-term pricing and margins for large pharma names like Bristol Myers Squibb. Article on Medicare drug price negotiation risk

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.